Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1822791 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $5.04Day +6.78%Mkt cap $64M1Y +44.4%Off 52W high −62.7%Vol (1Y) 110.8%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,363 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest7.2% of sh out |
| Days to cover18.4d |
| 13F net flow (QoQ)+0.56% |
| Top-10 13F concentration93.6% |
| Next report (est.)2026-08-13 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$134,000 |
| Earnings (TTM)-$33.5M |
| Net margin−13086.5% |
| Sales growth 3Y−24.9% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−14.1% |
| 1Y+44.4% |
| 3Y−67.5% |
| 5Y−97.1% |
| Since incept. (ann.)−52.1% |
Total return through 2026-07-30 · series begins 2021-02-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)110.8% |
| Ann. volatility (3Y)105.9% |
| Sharpe (1Y)0.91 |
| Sharpe (3Y)0.15 |
| Max drawdown (1Y)−68.6% |
| Max drawdown (3Y)−84.7% |
| Beta (3Y vs SPY)1.32 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Boxer Capital Management, LLC | 477,515 | $2M | 4.05% | +139.1% |
| SymBiosis Capital Partners, LLC | 431,094 | $2M | 3.66% | −44.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 308,230 | $2M | 2.62% | new |
| SCOGGIN MANAGEMENT LP | 300,000 | $1M | 2.55% | +9.1% |
| Ensign Peak Advisors, Inc | 257,872 | $1M | 2.19% | +125.5% |
| GEODE CAPITAL MANAGEMENT, LLC | 95,874 | $473,042 | 0.81% | +16.8% |
| Lunt Capital Management, Inc. | 52,260 | $257,642 | 0.44% | +0.0% |
| PEAK6 LLC | 50,012 | $246,559 | 0.42% | −50.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | — | — | $15,000 | −81.5% |
| 2025-12-31 | 2026-03-12 | — | — | $77,000 | −15.4% |
| 2025-09-30 | 2025-11-13 | — | — | $15,000 | −82.8% |
| 2025-06-30 | 2025-08-14 | — | — | $27,000 | −70.3% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-13 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Product 60% · Royalty 41%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
